ICO-007

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameICO-007
Drug Alias NameICO-007ISIS-13650IP-13650
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionC-Raf kinase inhibitors
TargetsC-Raf kinase
Therapy Area/IndicationsDiabetic macular oedema
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohns Hopkins UniversityIco Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedema

Other Information

ATC CodeN/A
Related LinksN/A